While this requires further verification, recent investigation on a hepatoma and breast cancer model point to the importance of AKT as an angiogenesis driver and the relevance of sorafenib in preventing HUVEC migration and capillary tube formation by dephosphorylating AKT [26,27]. Here, AKT1 is linked to hepatocellular carcinoma.